Results 231 to 240 of about 261,516 (285)

Effectiveness and Safety of Setmelanotide in a Patient With a Heterozygous PCSK1 Deficiency

Obesity, EarlyView.
ABSTRACT Setmelanotide, a melanocortin 4 receptor (MC4R) agonist, is a promising pharmacological treatment option for people with rare monogenic obesity conditions affecting the leptin‐melanocortin signaling pathway, including proprotein convertase subtilisin/kexin type 1 (PCSK1) gene mutations.
Ellina Lytvyak, Arshdeep Rattol, Eduardo Grunvald   +2 more
wiley   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu, Lee‐Yuan Lin, Jia‐Wei Sun, Wei‐Ting Yu, Fara Silvia Yuliani, Shyh‐Hsiang Lin   +5 more
wiley   +1 more source

Bariatric Surgery in Adolescents With Obesity: Weight and Cardiometabolic Outcomes—Real‐World Data

Obesity, EarlyView.
ABSTRACT Objective This study evaluated changes in weight status and cardiometabolic parameters following bariatric surgery (BS) among adolescents with obesity using population‐based real‐world data. Methods This retrospective cohort study used electronic health records from Clalit Health Services, Israel.
Shlomit Shalitin, Moshe Phillip, Michal Yackobovitch‐Gavan   +2 more
wiley   +1 more source

Time‐Restricted Eating Promotes Weight Loss and Favorable Changes in Adipose in Obesity: The TREAD Randomized Control Trial

Obesity, EarlyView.
ABSTRACT Objective Examine time‐restricted eating (TRE) as a strategy to promote weight loss and cardiometabolic health in adults with obesity. Methods TRE in obesity and ADipose Tissue (TREAD) was a single‐center 12‐week RCT, involving 1:1 randomization to 10‐h TRE versus standard of care (SOC) in adults with obesity (BMI 30–50 kg/m2) without diabetes
Michael J. Wilkinson, Erika Padilla, Yuqi Wang, Sawye Raygani, Emily N. C. Manoogian, Kyla Laing, Khang Tong, Lin Liu, David Van, Justina Nguyen, Alan R. Saltiel, Shannon M. Reilly, Monica O'Neal, Satchidananda Panda, Amit R. Majithia, Pam R. Taub   +15 more
wiley   +1 more source

The real measurement of non-HDL-cholesterol: Atherogenic cholesterol

, 2016
Millan J, Hernandez-Mijares A, Ascaso J, Blasco M, Brea A, Diaz A, Gonzalez-Santos P, Mantilla T, Pedro-Botet J, Pinto X, Grp Dislipemia Aterogenica Soc   +10 more
openaire   +2 more sources

Six‐ and Twelve‐Month Changes in Body Composition and 24‐h Energy Expenditure After a Very Low‐Calorie Ketogenic Diet

Obesity, EarlyView.
ABSTRACT Objective This study assessed changes in body composition and 24‐h energy metabolism at 6 and 12 months after initiation of a 1‐month very low‐calorie ketogenic diet (VLCKD) in women with obesity. Methods Seventeen women with obesity who completed a 1‐month VLCKD underwent a 4‐week transition phase with carbohydrate reintroduction, followed by
Alessio Basolo, Paolo Piaggi, Valentina Angeli, Paola Fierabracci, Chiara Bologna, Giordano Paolucci, Guido Salvetti, Luca Chiovato, Jonathan Krakoff, Alberto Landi, Ferruccio Santini   +10 more
wiley   +1 more source

SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity

Obesity, EarlyView.
ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter, Julie Mount, J. Martin Gibson, Joanne Webb, Cheryl Marler, Catherine Reed, Mugdha Gore, Wenyu Ye, Elisa Gomez Valderas, John Wilding, Naveed Sattar, Melanie J. Davies, Kamlesh Khunti, Richard Haynes, Rachel L. Batterham   +14 more
wiley   +1 more source

Prevalence of non‐alcoholic fatty liver disease and its association with different combinations of weight status and metabolic abnormalities in children aged 6–18 years

Pediatric Investigation, EarlyView.
Children with non‐overweight combined with metabolic risk factors might increase the risk of non‐alcoholic fatty liver disease (NAFLD). These findings suggest that overweight and obesity should not be the sole criterion for NAFLD screening in children. In particular, more attention should be given to non‐overweight combined with metabolic abnormalities
Peiyu Ye, Luting Peng, Liwang Gao, Xiaonan Li, Qin Liu, Pei Xiao, Liang Wang, Xiaoyan Shi, Jun Ma, Yanhui Dong, Dongling Dai, Qinghua Yang, Xinchun Chen, Xin Fan, Naijun Wan, Jin Zhang, Bin Li, Lin Zhou, Guangsheng Wu, Lin Yang, Yan He, Yinkun Yan, Jie Mi   +22 more
wiley   +1 more source

Evidence map and gap analysis of metabolic change in pediatric growth hormone deficiency treated with growth hormone

Pediatric Investigation, EarlyView.
This evidence map of 63 studies (n = 6158) showed growth hormone therapy in children with growth hormone deficiency has neutral glucose effects, mixed lipid outcomes, potential benefits for bone mineral density, bone mineral content, and parathyroid hormone, but generally no impact on thyroid function, body composition, or body mass index.
Wei Wu, Ningyi Song, Yue Zhao, Caiqi Du, Yuning Zhao, You Wu, Xiaoping Luo   +6 more
wiley   +1 more source

Emerging Significance of Measuring Non HDL - Cholesterol in CAD

Journal of Medical Science And Clinical Research, 2017
openaire   +1 more source